• Ochre Bio

  Participated · Series A · Oct 2022

  Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases using deep phenotyping, precision RNA medicine, and testing in live human donor livers. The company has generated spatial‑sequencing, single‑cell sequencing, and imaging data in over 1,000 diseased human livers across three continents. Ochre has launched 'Liver ICUs' across the US to test RNA‑based drug candidates directly in human livers. Proceeds from the Series A will be used to translate discovery research into RNA drug candidates and to fund human liver preclinical testing in 2023 to select therapies for clinical development in 2024. The company plans to broaden its discovery and development platforms, including a state‑of‑the‑art RNA chemistry platform and an exploratory platform to expand research into a wider set of liver diseases. Ochre's longer‑term goals include regenerating organs in patients and improving the viability of marginal donor livers to reduce the need for transplants. Ochre Bio develops RNA medicines for chronic liver diseases and uses deep phenotyping ('phenomics') to digitize liver biology at scale. The company has generated large amounts of spatial genomics data from freshly donated human livers and uncovered hundreds of novel potential liver targets that are being validated in their labs. By 2022, Ochre plans to build a complete in silico human liver of over 10^11 measurements to predict the effect of perturbing any gene in major liver cell types. In addition to computational work, Ochre tests therapeutics in explanted human livers maintained extracorporeally and has developed a full-stack GalNAc-siRNA development process validated in actively perfused human livers. Planned uses of recent funding include advancing RNA therapies, expanding the deep phenotyping platform, onboarding five transplant center partners to test therapies on discarded donor livers, and moving products toward clinical development; the company also opened a Taiwanese lab to study liver disease in Asia. Ochre is based in Oxford, England and is built on over 15 years of experience in liver genomics and advanced therapies.

• Halio

  Participated · Series C · Jan 2017

  HALIO develops electrochromic smart glass, marketed as the industry’s fastest and most advanced solution for dynamic daylight control and solar heat management. Its product suite includes windows and skylights with Sky Camera, tint algorithms, and control automation that switch tints within seconds to optimize comfort and glare. HALIO states its technology can reduce a building’s operational energy use by up to 22% and decrease peak demand by 25% (Red Car Analytics, Nov 2019). HALIO products are available directly and through third‑party fabricators such as Viracon and GLASSBEL. The company emphasizes aesthetic facades, occupant wellness, and real‑time energy optimization as core benefits. Recent leadership change names Doug Schendt as CEO, succeeding Bruce Sohn, who is retiring. Halio develops and commercializes electrochromic smart glass and an integrated cloud-based AI control system that maximizes natural light while mitigating solar heat and glare. The company positions its solution as the industry’s most advanced smart glass, emphasizing clarity, fast switching, smooth transitions, and durability proven in harsh environments. Halio’s platform is specified by leading architects, is co-branded by partners such as Viracon and Marvin, and integrates IoT standards like Matter and third-party systems including Siemens’ Connect Ecosystem, Amazon Alexa, Crestron, and Apple HomeKit. The technology is claimed to reduce a building’s energy consumption by up to 20% while improving occupant health and productivity. Halio says it has a growing backlog of designs and is increasing production through a partnership with Viracon to service orders. Funding is intended to expand production capability and further advance its electrochromic technology for commercial buildings, residential homes, and vehicles. The company is based in Hayward, Calif. Kinestral Technologies develops and manufactures Halio, an advanced smart-tinting glass product sold for buildings and homes. Halio is sold exclusively through joint ventures Halio North America and Halio International, which Kinestral formed with AGC, Inc. The product is available in over 30 countries. The company is led by CEO S.B. Cha and focuses on turning glass into intelligent architectural elements. Kinestral closed a major financing that strengthens its balance sheet and supports growth plans. The company intends to use the proceeds to expand manufacturing, sales, and installation of Halio smart-tinting glass. Kinestral Technologies’ flagship product is Halio, an electrochromic smart‑tinting glass that tints to cool grays and can reach its darkest shade in under three minutes. Halio supports an unlimited number of tint levels, can be fully automated to respond to weather and occupant preferences, and allows manual override. The glass is offered in sizes up to 5 x 10 feet and is positioned for integration into smart homes and buildings. Halio is sold exclusively through Halio North America and Halio International, joint ventures Kinestral formed with AGC. Kinestral reports a growing global patent portfolio in manufacturing, device processing, and smart window control systems. The company is headquartered in the San Francisco Bay Area and is pursuing integrations with building management systems to drive energy efficiency and improved occupant comfort. Kinestral Technologies develops Halio™, a smart-tinting glass system that shades and protects from sun glare within seconds and reaches a desired tint within three minutes. In its clear state Halio is indistinguishable from ordinary glass and tints to a range of neutral grays intended to complement design palettes. The company highlights applications in smart homes and buildings to improve occupant comfort, well‑being, and energy efficiency, and notes Halio can be used for interior walls. Kinestral says it has a growing global patent portfolio in manufacturing, device processing, and smart window control systems. Halio is available in selected markets today, and the company plans a North American launch later this year followed by global expansion in 2018. Kinestral is headquartered in the San Francisco Bay Area and recently closed a $65 million Series C financing to support commercialization.

No current team members are available.